News and updates from the PANORAMIC team
12 April 2022
From today, the antiviral treatment Paxlovid has been included in the national PANORAMIC study, the UK’s fastest ever recruiting clinical trial of its kind, run by the Nuffield Department of Primary Care Health Sciences and supported by the National Institute for Health and Care research (NIHR).
8 March 2022
New Story from the BBC: People in Northern Ireland are being urged to take part in a study which will help decide how antiviral drugs will be used to treat Covid-19.
14 February 2022
Researchers studying the use of an antiviral drug people can take at home to treat Covid want thousands more volunteers to join their trial. Scientists at Oxford and Southampton Universities are looking at how molnupiravir can reduce symptoms in people at risk of serious illness. They have signed up 8,000 recently diagnosed with the virus but want thousands more to join the trial.
19 January 2022
BBC Inside Health speak to Nerys from North Wales who has started antiviral treatment for her COVID-19 infection. They also explore the new drugs with virologist Dr Elisabetta Groppelli and Professor Chris Butler who is running the clinical trial designed to pinpoint who is likely to benefit from antivirals the most. (Skip to 15min in for anti-virals).
18 January 2022
The recent decision by regulators to approve the antiviral agent Paxlovid for use in the UK adds a formidable new weapon to the arsenal of treatments for COVID-19.
18 January 2022
Treatments like sotrovimab, molnupiravir and Paxlovid could lead to a new strategy in 2022: tackling COVID-19 soon after infection to prevent severe symptoms from developing
8 December 2021
Researchers from the University of Oxford have today started recruiting participants for a first-of-its-kind clinical trial to test novel antiviral COVID-19 treatments for use early on in the illness by people in the community with COVID-19 and those who are at higher risk of complications – partnering with the National Institute for Health Research (NIHR) and working with colleagues in several UK universities, and the NHS UK-wide.